Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.
Oncotarget
; 9(25): 17270-17281, 2018 Apr 03.
Article
in En
| MEDLINE
| ID: mdl-29707107
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
Oncotarget
Year:
2018
Type:
Article
Affiliation country:
Germany